Crispr Therapeutics AG (CRSP)

$41.58

up-down-arrow $0.22 (0.53%)

As on 16-Jun-2025 16:00EDT

Value Research Rating

--

Quality Score fund-quick-summary-circle

0/0

Growth Score fund-quick-summary-circle

0/0

Valuation Score fund-quick-summary-circle

0/0

Momentum Score fund-quick-summary-circle

0/0

Crispr Therapeutics AG (CRSP) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...
loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 40.76 High: 42.35

52 Week Range

Low: 30.04 High: 63.68

Liquidityliquidity

Low Moderate High

Fundamentals

  • Market capMarket cap information

    $3,572 Mln

  • Revenue (TTM)Revenue (TTM) information

    $37 Mln

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -0.2 %

  • ROCEROCE information

    -- %

  • P/E RatioP/E Ratio information

    --

  • P/B RatioP/B Ratio information

    2

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    14.2

  • Div. YieldDiv. Yield information

    0 %

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $-4.5

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    86,363,696

10 Years Aggregate

CFO

$-565.84 Mln

EBITDA

$-1,028.68 Mln

Net Profit

$-997.30 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Crispr Therapeutics AG (CRSP)
5.6 14.5 -1.3 -34.6 -12.8 -7.8 --
BSE Sensex*
4.3 -0.9 10.5 6.0 16.6 19.4 11.8
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 16-Jun-2025  |  *As on 17-Jun-2025  |  #As on 26-Oct-2023
Company
2023
2022
2021
2020
2019
2018
2017
Crispr Therapeutics AG (CRSP)
54.0 -46.4 -50.5 151.4 113.2 21.5 15.9
S&P Small-Cap 600
13.9 -17.4 25.3 9.6 20.9 -9.7 11.7
BSE Sensex
18.7 4.4 22.0 15.8 14.4 5.9 27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View Details
loading...

loading...

loading...

5Y Avg -- 3Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peers

View Details
Company
Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Crispr Therapeutics AG (CRSP)
41.6 3,572.0 37.0 -385.7 -1,282.9 -20.5 -- 2.0
1.9 195.8 28.3 -52.1 -183.5 -46.3 -- 1.7
3.4 355.2 70.2 -149.8 -104.3 -- -- 2.6
0.1 2.9 7.0 -8.5 -181.4 -- -- 5.0

Shareholding Pattern

View Details
loading...

About Crispr Therapeutics AG (CRSP)

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The...  company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.  Read more

  • CEO & Chairman

    Dr. Samarth Kulkarni Ph.D.

  • CEO & Chairman

    Dr. Samarth Kulkarni Ph.D.

  • Headquarters

    Zug

  • Website

    https://www.crisprtx.com

Edit peer-selector-edit
loading...
loading...

FAQs for Crispr Therapeutics AG (CRSP)

The total asset value of Crispr Therapeutics AG (CRSP) stood at $ 2,286 Mln as on 31-Mar-25

The share price of Crispr Therapeutics AG (CRSP) is $41.58 (NASDAQ) as of 16-Jun-2025 16:00 EDT. Crispr Therapeutics AG (CRSP) has given a return of -12.78% in the last 3 years.

Crispr Therapeutics AG (CRSP) has a market capitalisation of $ 3,572 Mln as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Crispr Therapeutics AG (CRSP) is 1.95 times as on 13-Jun-2025, a 24% discount to its peers’ median range of 2.58 times.

Since, TTM earnings of Crispr Therapeutics AG (CRSP) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Crispr Therapeutics AG (CRSP) and enter the required number of quantities and click on buy to purchase the shares of Crispr Therapeutics AG (CRSP).

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

The CEO & director of Dr. Samarth Kulkarni Ph.D.. is Crispr Therapeutics AG (CRSP), and CFO & Sr. VP is Dr. Samarth Kulkarni Ph.D..

There is no promoter pledging in Crispr Therapeutics AG (CRSP).

Crispr Therapeutics AG (CRSP) Ratios
Return on equity(%)
-20.47
Operating margin(%)
-1282.89
Net Margin(%)
-1042.77
Dividend yield(%)
--

No, TTM profit after tax of Crispr Therapeutics AG (CRSP) was $0 Mln.